Indian Growth Compounder Screening

When to use

When the user asks to find Indian growth / compounding companies rather than strict early-phase S-curve plays, or says there are "no real S-curves in India." This is the pragmatic alternative to the S-curve scorecard (see indian-stock-sector-screening / s-curve-stock-screening, which are user-owned and kept separate).

Origin (2026-08): the investor rejected the strict S-curve framing, arguing India's growth names are mostly (a) penetration/cyclical, (b) margin-led, or (c) market-share — none fit the clean "sub-15% penetration + >20% revenue CAGR" archetype. Forcing everything through it discards good compounders. Use this lens instead.

Core thesis: compounder ≠ S-curve

A growth compounder is distinct from an S-curve stock:

Dimension	S-curve	Growth Compounder
Primary gate	Revenue CAGR > 20% sustained	Earnings (PAT) CAGR > 20% sustained
Growth source	New market penetration	Margin expansion, market share, mix shift
Valuation anchor	PEG (still important)	PEG (still important)
Quality bar	ROCE > 15%	ROCE > 15%, ideally 20%+
Exit trigger	Revenue deceleration 3+ qtrs	PAT deceleration / margin compression / promoter selling
Risk	Adoption fails	AI/structural disruption of the model

Sub-20% revenue CAGR is NOT a pass under this lens (it IS under S-curve). A company growing revenue 15% but expanding margin 19%→33% PAT CAGR is a valid compounder.

Workflow

1. Screen for the pure-play profile

Across sectors (not one sector at a time), look for:

• Business IS the growth story — dominant exposure, not a conglomerate where the growth division is 10% of earnings.
• PAT CAGR > 20% (5Y and especially 3Y/TTM trend) — check whether it's accelerating or decelerating.
• Margin-led growth confirmed — OPM trend expanding, and profit growth faster than revenue growth (that gap is the compounding engine).
• Quality: ROCE > 15% (ideally 20%+), ROE > 15%, low debt, healthy CFO/PAT.
• Valuation via PEG = PE ÷ lower of 3Y and 5Y PAT CAGR. PEG < 1.5 strong, < 2 acceptable, > 2 prices in the growth. Flag >500bps 3Y-vs-5Y divergence as deceleration.
• Smart money: stable/increasing promoter + rising FII/DII. Promoter selling >5% is a hard stop.
• Working capital hygiene: debtor/inventory days not deteriorating (worsening debtor days = earnings quality red flag).

2. Pull live data

Use Screener.in standalone pages (see the indian-stock-analysis skill for the stable extraction workflow):

• Summary snapshot: CMP, P/E, Market Cap, ROCE, ROE, Div Yield (always visible on standalone page, no login).
• Cross-domain peer table on the largest/leader's page gives CMP, P/E, MCap, % yield, ROCE and quarterly growth for the whole peer group in ONE navigation.
• CAGR tables (Compounded Sales/Profit Growth, 5Y/3Y/TTM) and OPM trend from Ratios.

3. Rank & verdict

• 🟢 BUY/compound — PAT CAGR > 20% accelerating, ROCE > 20%, PEG < 1.5, no promoter selling.
• 🟡 WATCH — quality but expensive (PEG > 2), or one red flag (deteriorating working capital, lumpy quarters).
• 🔴 PASS — PAT CAGR < 20% with no margin story, ROCE < 15%, promoter selling, weakening working capital.

4. Write-up

Follow the user's output conventions: nested bullet lists in responses (NOT markdown tables — he finds tables hard to read on Slack). Save full analysis files to /opt/data/wiki/wealth/invest/research/ if a persistent watchlist is wanted.

Pitfalls

1. Don't reject sub-20% revenue growth outright — it may be a margin-led compounder. Check the revenue→PAT gap.

2. Stock-price CAGR ≠ business quality. A stock can fall −38% over 1Y while fundamentals grow — that divergence is often the compounding entry, but verify it's a rerating and not a broken business.

3. Large-caps (TCS/Infosys/HCL/LTIM) are dividend compounders, not growth sleeve. Single/low-double-digit revenue growth belongs in the dividend portfolio.

4. Beware overstated "other income" inflating PAT (Screener flags it in CONS — e.g., Zensar ₹282 Cr). Strip it before computing sustainable PAT CAGR.

5. Lumpy quarters (esp. in a growth stock like Coforge) — use CAGR/trend, not single-quarter spikes.

6. AI disruption overhang applies to every services/model business — monitor margin compression as the tell, not just revenue.

Reference

• Worked example (IT services screen: Zensar vs Persistent vs Coforge vs Birlasoft): references/it-services-compounder-screen.md
• User-owned related skills (analogous domain, kept separate — do not edit): s-curve-stock-screening, indian-stock-sector-screening, indian-stock-analysis.

Review cadence

• Quarterly: update PAT CAGR trend, OPM, working capital, promoter/FII.
• Annual: full re-score, verify margin story still holds.
• Stock movement > 20%: check if thesis changed vs noise.
• See also indian-stock-analysis for deep-dive template and technicals.